LEAD-452

LEAD-452 is a humanized bispecific EGFR-targeted 4-1BB-agonistic trimerbody developed by LeadArtis. It is designed to provide enhanced tumor-specific costimulation by simultaneously targeting the epidermal growth factor receptor (EGFR) and activating the 4-1BB (CD137) pathway, which plays a key role in T-cell activation and anti-tumor immune responses. Preclinical studies have demonstrated that LEAD-452 can induce complete cancer regression in mouse models of colon tumors and shows promising safety and efficacy profiles. It is currently in preclinical development for solid tumors including colon cancer, breast cancer, and head and neck neoplasms.